Select Publications from NYU CPM Faculty and Affiliates

Raison CL, Sanacora G, Woolley J, et al. Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA. Published online August 31, 2023. doi:10.1001/jama.2023.14530

Zeifman, Richard J; Kettner, Hannes; Pagni, Broc A; Mallard, Austin; Roberts, Daniel E; Erritzoe, David; Ross, Stephen; Carhart-Harris, Robin L. Co-Use Of MDMA With Psilocybin/LSD May Buffer Against Challenging Experiences and Enhance Positive Experiences. Scientific Reports. 2023 Aug 22; 13(1):13645

Gold, N.D., Mallard, A. J., Hermann, J. C., Zeifman, R. J., Pagni, B., Bogenschutz, M., & Ross, S. (2023). Exploring the potential utility of psychedelic therapy for patients with amyotrophic lateral sclerosisJournal of Palliative Medicine. Advance online publication.

Zeifman, R. J., Wagner, A. C., Monson, C. M., & Carhart-Harris, R. (2023). How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change. Journal of Affective Disorders, 334, 100-112.

Kelley C. O’Donnell, Daniel E. Roberts, Terence H.W. Ching, Gianni Glick, Noam Goldway, Natalie Gukasyan, Jamila Hokansen, Benjamin Kelmendi, Stephen Ross, Mary E. Yaden, and Christopher Pittenger. Letter to the Editor: What Is in a Name? The Many Meanings of “Psychedelic”. Psychedelic Medicine.

Gold ND, Podrebarac SK, White LA, Marini C, Simon NM, Mittelman MS, Ross S, Bogenschutz MP, Petridis PD. Examining the Rationale for Studying Psychedelic-Assisted Psychotherapy for the Treatment of Caregiver Distress. Psychedelic Medicine.

Marini C, Northover NS, Gold ND, Rogers UK, O’Donnell KC, Tofighi B, Ross S, Bogenschutz B. (2023). A Systematic Approach to Standardizing Drinking Outcomes From Timeline Followback Data. Subst Abuse. Vol. 17 Pages 11782218231157558. doi: 10.1177/11782218231157558

Carhart-Harris RL, Chandaria S, Erritzoe DE, Gazzaley A, Girn M, Kettner H, Mediano PAM, Nutt DJ, Rosas FE, Roseman L, Timmermann C, Weiss B, Zeifman RJ, Friston KJ. (2023). Canalization and plasticity in psychopathology. Neuropharmacology. 2023 Mar 15;226:109398. doi: 10.1016/j.neuropharm.2022.109398.

Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laska E, Mennenga SE, O’Donnell K, Owens LT, Podrebarac S, Rotrosen J, Tonigan JS, Worth L. (2022). Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical TrialJAMA Psychiatry. 2022;79(10):953–962.

O’Donnell KC, Mennenga SE, Owens L, Podrebarac SK, Baron T, Rotrosen J, Ross S, Forcehimes AA, Bogenschutz MP. (2022). Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial. Contemporary Clinical Trials, 2022 Dec;123:106976. doi: 10.1016/j.cct.2022.106976

Traynor JM. Roberts DE, Ross S, Zeifman R, Choi-Kain L. (2022). MDMA-Assisted Psychotherapy for Borderline Personality Disorder. FOCUS, 20(4), 358-367.

Kim, K., Roberts, D. (2022). Hallucinogen-Related Disorders. In: Avery, J.D., Hankins, D. (eds) Addiction Medicine. Psychiatry Update, Volume 2. Springer, Cham.

Mathai DS, Yaden DB, O’Donnell KC. The conundrum of therapeutic intoxication. (2022). Br J Psychiatry. Aug;221(2):496-497. doi: 10.1192/bjp.2022.58

Mathai DS, Lee SM, Mora V, O’Donnell KC, Garcia-Romeu A, Storch EA. Mapping consent practices for outpatient psychiatric use of ketamine. (2022). J Affect Disord. Sep 1;312:113-121. doi: 10.1016/j.jad.2022.06.036.

Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., … & Doblin, R. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 studyNature Medicine27(6), 1025-1033.

Podrebarac SK, O’Donnell KC, Mennenga SE, Owens LT, Malone TC, Duane JH, Bogenschutz MP. (2021). Spiritual Experiences in Psychedelic-Assisted Psychotherapy: Case Reports of Communion With the Divine, the Departed, and Saints in Research Using Psilocybin for the Treatment of Alcohol Dependence. Spirituality in Clinical Practice, 8(3), 177–187.

Agin-Liebes GI, Malone T, Yalch MM, Mennenga SE, Ponté KL, Guss J, Bossis AP, Grigsby J, Fischer S, Ross S. (2020). Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol. Feb;34(2):155-166. doi: 10.1177/0269881119897615.

O’Donnell, KC, Mennenga, SE, & Bogenschutz, MP. (2019). Psilocybin for depression: Considerations for clinical trial designJournal of Psychedelic Studies, 3(3), 269-279.

Malone TC, Mennenga SE, Guss J, Podrebarac SK, Owens LT, Bossis AP, Belser AB, Agin-Liebes G, Bogenschutz MP, Ross S. (2018). Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy. Front Pharmacol. Apr 3;9:256.

Ross S. (2018). Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress. Int Rev Psychiatry. 2018 Aug;30(4):317-330. doi: 10.1080/09540261.2018.1482261.

Bogenschutz MP, Podrebarac SK, Duane JH, Amegadzie SS, Malone TC, Owens LT, Ross S, Mennenga SE. (2018). Clinical Interpretations of Patient Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder. Front Pharmacol. Feb 20;9:100.

Nielson EM, May DG, Forcehimes AA, Bogenschutz MP. (2018). The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions. Front Pharmacol. Feb 21;9:132.

Bogenschutz MP, Ross S. Therapeutic Applications of Classic Hallucinogens. (2018). Curr Top Behav Neurosci. 2018;36:361-391. doi: 10.1007/7854_2016_464.

Bogenschutz MP. It’s time to take psilocybin seriously as a possible treatment for substance use disorders. (2017). Am J Drug Alcohol Abuse. 2017 Jan;43(1):4-6. doi: 10.1080/00952990.2016.1200060.

Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, Mennenga SE, Belser A, Kalliontzi K, Babb J, Su Z, Corby P, Schmidt BL. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016 Dec;30(12):1165-1180.

Bogenschutz MP, Johnson MW. (2016). Classic hallucinogens in the treatment of addictions. Prog Neuropsychopharmacol Biol Psychiatry. 2016 Jan 4;64:250-8. doi: 10.1016/j.pnpbp.2015.03.002.

Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ. (2015). Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. 2015 Mar;29(3):289-99. doi: 10.1177/0269881114565144.

Bogenschutz MP. (2013). Studying the effects of classic hallucinogens in the treatment of alcoholism: rationale, methodology, and current research with psilocybin. Curr Drug Abuse Rev. 2013 Mar;6(1):17-29. doi: 10.2174/15733998113099990002.

Ross S. (2012). Serotonergic hallucinogens and emerging targets for addiction pharmacotherapies. Psychiatr Clin North Am. 2012 Jun;35(2):357-74. doi: 10.1016/j.psc.2012.04.002.